{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+injection&page=3",
    "query": {
      "intervention": "Subcutaneous injection",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 3857,
    "total_pages": 386,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+injection&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+injection&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T14:08:00.569Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07159763",
      "title": "A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "MK-1406",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 10000,
      "start_date": "2025-09-25",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-15T14:08:00.569Z",
      "location_count": 120,
      "location_summary": "Anniston, Alabama • Cullman, Alabama • Glendale, Arizona + 104 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07159763"
    },
    {
      "nct_id": "NCT06598306",
      "title": "Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extensive Stage Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Tarlatamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2024-10-07",
      "completion_date": "2030-04-24",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-15T14:08:00.569Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06598306"
    },
    {
      "nct_id": "NCT00819806",
      "title": "CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NY-ESO-1-expressing Tumors"
      ],
      "interventions": [
        {
          "name": "Vaccine only",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaccine + cyclophosphamide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hassane M. Zarour, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2009-01",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-31",
      "last_synced_at": "2026-10-15T14:08:00.569Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00819806"
    },
    {
      "nct_id": "NCT01543204",
      "title": "Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2012-02-01",
      "completion_date": "2015-05-29",
      "has_results": true,
      "last_update_posted_date": "2017-12-29",
      "last_synced_at": "2026-10-15T14:08:00.569Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01543204"
    },
    {
      "nct_id": "NCT06462547",
      "title": "ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gene Mutations",
        "Pseudoxanthoma Elasticum",
        "Arterial Calcification",
        "Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency",
        "Autosomal Recessive Hypophosphatemic Rickets Type 2"
      ],
      "interventions": [
        {
          "name": "INZ-701",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inozyme Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 22,
      "start_date": "2024-06-19",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-15T14:08:00.569Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Eatontown, New Jersey",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Eatontown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06462547"
    },
    {
      "nct_id": "NCT01705587",
      "title": "Fracture (FX) Improvement With Teriparatide: FiX-IT Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoporosis",
        "Atypical Femoral Fracture"
      ],
      "interventions": [
        {
          "name": "teriparatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Susan L. Greenspan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 13,
      "start_date": "2012-12",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-10-15T14:08:00.569Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01705587"
    },
    {
      "nct_id": "NCT02758132",
      "title": "Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Denosumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Hawaii",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1,
      "start_date": "2016-03-01",
      "completion_date": "2016-09-06",
      "has_results": true,
      "last_update_posted_date": "2019-11-08",
      "last_synced_at": "2026-10-15T14:08:00.569Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02758132"
    },
    {
      "nct_id": "NCT00288704",
      "title": "Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Cold Autoinflammatory Syndrome (FCAS)",
        "Familial Cold Urticaria",
        "Muckle-Wells Syndrome (MWS)",
        "Genetic Diseases, Inborn"
      ],
      "interventions": [
        {
          "name": "rilonacept 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2005-12",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2011-12-06",
      "last_synced_at": "2026-10-15T14:08:00.569Z",
      "location_count": 24,
      "location_summary": "Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Stuart",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00288704"
    },
    {
      "nct_id": "NCT00085098",
      "title": "Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain Tumor",
        "Central Nervous System Tumor"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "3 Years to 25 Years"
      },
      "enrollment_count": 24,
      "start_date": "2007-01",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2018-09-07",
      "last_synced_at": "2026-10-15T14:08:00.569Z",
      "location_count": 95,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 80 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085098"
    },
    {
      "nct_id": "NCT03375463",
      "title": "A Study of Tirzepatide (LY3298176) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 52,
      "start_date": "2017-12-19",
      "completion_date": "2018-12-27",
      "has_results": true,
      "last_update_posted_date": "2024-02-05",
      "last_synced_at": "2026-10-15T14:08:00.569Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03375463"
    }
  ]
}